Discounted for Margin and Peer Weakness
Boston Scientific trades at a discount for understandable reasons. Margins and ROIC lag sector leaders, and segment headwinds persist. In medtech, that’s a problem. Only a clear margin recovery and market share gains would shift the market’s view.
Published by AssetNext · 2026-05-28
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-07-10 | Profile and price weak | 55 | -58.6% | -14.5% |
Break down BSX's structural position across all peer dimensions with the interactive app.